



**Date: 21 November 2017**

**Sydney, Australia**

**ASX: NOX**

**Noxopharm Limited**

ABN 50 608 966 123

**Registered Office:**

Suite 1 Level 6  
50 Queen St  
Melbourne VIC 3000  
Australia

**Operational Office:**

Suite 3, Level 4  
828 Pacific Highway  
Gordon NSW 2072  
Australia

**Board of Directors**

**Mr Peter Marks**

Chairman  
Non-Executive  
Director

**Dr Graham Kelly**

Chief Executive Officer  
Managing Director

**Dr Ian Dixon**

Non-Executive  
Director

ASX Limited  
20 Bridge Street  
SYDNEY NSW 2000

## **COMPLETION OF TRANSFER OF SHARES TO NYRADA INC.**

**Sydney, 21 November 2017:** Following the approval by members of the resolutions being passed at the Extraordinary General Meeting held on 6 November 2017, Noxopharm Limited (ASX:NOX) is pleased to announce that the transfer of shares underlying the establishment of US subsidiary, Nyrada Inc, has been completed.

Noxopharm has transferred shares in Norbio No. 1 Pty Ltd ACN 619 956 722 and Norbio No. 2 Pty Ltd ACN 619 956 973 to Nyrada Inc in consideration for 6,669 shares in Nyrada. Further, Altnia Holdings Pty Ltd ACN 133 349 238 as trustee for the I. Dixon Family Trust has completed the transfer of the total issued share capital of Cardio Therapeutics Pty Ltd ACN 167 825 201 to Nyrada in consideration for 3,329 shares in Nyrada.

As announced on 25 September 2017, Noxopharm has formed Nyrada as a US subsidiary company as a non-oncology drug development business.

After completion of the transfer of shares to Nyrada by Noxopharm and Altnia, Nyrada now owns the intellectual property rights in three non-oncology drug programs.

Commenting on completion, Noxopharm CEO, Dr Graham Kelly, said "The establishment of Nyrada has a dual purpose. The first is to allow Noxopharm to focus its resources on its core aim of bringing NOX66 to market as a major new oncology drug, an opportunity in my view so substantial that it requires clear focus. The second is to provide a means of developing valuable intellectual property that otherwise would risk being sidelined by the need to focus on NOX66."

"Noxopharm shareholders now have a two-thirds stake in a company that I am confident has a strong future as a drug developer. Nyrada starts life with 3 first-in-class drugs that it owns outright and that address substantial community problems associated with brain and nerve damage, auto-immune diseases of the gut, and high blood cholesterol."

### **About Noxopharm Ltd**

Noxopharm is an Australian drug development company with offices in Sydney and Hong Kong. The Company has a primary focus on the development of drugs to address the problem of resistance in cancer cells to radiotherapy and chemotherapy, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates under development.

**About Nyrada Inc**

Nyrada is a US drug development company that is being established in the State of New York. The Company has a primary focus on the development of small molecule drugs to address major unmet needs in diseases of the brain and peripheral nerves, auto-immune diseases of the bowel, and hypercholesterolemia. It has 3 drugs in pre-clinical programs designated NYX-104, NYX-205 and NYX-330.

**Investor & Corporate Enquiries:**

Prue Kelly

M: 0459 022 445

E: [info@noxopharm.com](mailto:info@noxopharm.com)

**Company Secretary :**

David Franks

T: +61 2 9299 9690

E: [dfranks@fa.com.au](mailto:dfranks@fa.com.au)

[www.noxopharm.com](http://www.noxopharm.com)

**Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.